Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sleep Apnea

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MT-MRI for detection of renal interstitial fibrosis in renovascular disease.

Scientific reports·2026

Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026

Same author

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

American journal of clinical dermatology·2026

Same author

Acute Cardiovascular Responses to Amphetamine/Dextroamphetamine Salts (Adderall) in Adderall-Naïve Young Adults: A Randomized Clinical Trial.

Mayo Clinic proceedings·2026

Same author

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

The Journal of dermatology·2026

Same author

Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib.

Dermatology and therapy·2026

Same journal

A reality check for mHealth sleep apps: bridging the empirical void in digital sleep health.

Sleep·2026

Same journal

Sleep, circadian, and mental health in neurodivergent neurotypes: Lived experience perspective on the research landscape and roadmaps.

Sleep·2026

Same journal

Nighttime light exposure is associated with metabolic dysfunction in schizophrenia: A cross-sectional analysis of the LENS study.

Sleep·2026

Same journal

Sleep Need Outcompetes Preparation: Reframing Sleep Initiation Through Naturalistic Behaviour.

Sleep·2026

Same journal

The Quest for Automated Pediatric Sleep Scoring: Are We There Yet?

Sleep·2026

Same journal

Sex Differences in the Sleep Architecture and Sleep-Disordered Breathing in C57BL/6 J Mice.

Sleep·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Obstructive sleep apnea and aldosterone.

Anna Svatikova¹, Lyle J Olson, Robert Wolk

¹Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.

|January 1, 2010

Summary

This summary is machine-generated.

Obstructive sleep apnea (OSA) does not acutely affect aldosterone or plasma renin activity (PRA) levels in patients without cardiovascular disease. These hormonal levels remained similar between OSA patients and healthy individuals, even during untreated sleep apnea.

Related Experiment Videos

Last Updated: Jun 17, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Area of Science:

Cardiology
Sleep Medicine
Endocrinology

Background:

Obstructive sleep apnea (OSA) is a significant risk factor for hypertension and cardiovascular morbidity.
A dysregulated renin-angiotensin-aldosterone system (RAAS) may contribute to sodium retention and hypertension in OSA.
The potential activation of RAAS in OSA warrants investigation.

Purpose of the Study:

To test the hypothesis that aldosterone and plasma renin activity (PRA) are increased by apneic sleep in subjects without cardiovascular disease.
To compare RAAS markers in individuals with moderate to severe OSA versus healthy controls.

Main Methods:

Measured plasma aldosterone and PRA in 21 OSA patients and 19 healthy controls.
Collected samples at baseline (9 pm), during untreated OSA (2 am), and post-awakening (6 am).
Assessed the impact of continuous positive airway pressure (CPAP) treatment on these markers.

Main Results:

No significant baseline differences in aldosterone or PRA between OSA patients and healthy controls.
Neither untreated OSA nor CPAP treatment acutely altered aldosterone or PRA levels in OSA patients.
Both groups exhibited diurnal variation, with higher morning levels of aldosterone and PRA compared to nighttime levels.

Conclusions:

Patients with moderate to severe OSA and no co-existing cardiovascular disease have normal plasma aldosterone and renin levels.
Acute effects of untreated OSA or CPAP treatment on plasma aldosterone and renin are not observed.